Cyclin E amplification, a novel mechanism of resistance to trastuzumab in HER2 amplified breast cancer Sunday, Apr 18, 2010, 2:25 PM - 2:40 PM
|
|
- Byron Owen
- 5 years ago
- Views:
Transcription
1 Abstract Print View Page 1 of 1 Presentation Abstract Abstract Number: Presentation Title: Presentation Time: Location: Author Block: 22 Cyclin E amplification, a novel mechanism of resistance to trastuzumab in HER2 amplified breast cancer Sunday, Apr 18, 2010, 2:25 PM - 2:40 PM Room 103, Washington Convention Center Maurizio Scaltriti 1, Pieter Eichhorn 1, Magui Gili 1, Marta Guzman 1, Claudia Aura 1, José Jimenez 1, Ludmila Prudkin 1, Simon R. Green 2, Javier Cortés 1, Sarat Chandarlapaty 3, Sabine Mai 4, Clifford A. Hudis 3, Neal Rosen 3, José Baselga 1. 1 Vall d'hebron Univ. Hospital, Barcelona, Spain; 2 Cyclacel, Dundee, United Kingdom; 3 Memorial Sloan-Kettering Cancer Center, New York, NY; 4 Manitoba Institute of Cell Biology, Winnipeg, MB, Canada Abstract Body: HER2 amplification/overexpression occurs in 20% of breast cancers and is associated with poor prognosis. Therapeutic agents against HER2, including monoclonal antibodies and tyrosine kinase inhibitors, have shown to improve the survival of these patients. However, primary and acquired resistance to these agents is a major barrier to the effective treatment of this disease. Aiming to identify the molecular pathways responsible for resistance to anti-her2 therapy we have established HER2 positive breast cancer cell lines refractory to the anti-proliferative effects of the therapeutic antibody trastuzumab. We have studied their acquired genetic aberrations by performing gene expression microarray and genome single nucleotide polymorphisms analyses. In trastuzumab resistant cells we identified an increase in copy number variation in locus 19q12. This chromosome region comprises seven genes, among them cyclin E1 (CCNE1). We further confirmed Cyclin E over-expression in trastuzumab resistant cells by western blot. To test the hypothesis that increased cyclin E expression could play a role in the acquisition of trastuzumab resistance we have demonstrated that ablation of cyclin E expression by sirna restores trastuzumab sensitivity in HER2 positive resistant cells. Furthermore, we have determined that trastuzumab resistant cells are highly sensitive to the specific CDK inhibitor seliciclib and its more potent derivative Cmpd. 5 (Cyclacel) both in vitro and in vivo. In addition, we have analyzed a cohort of HER2 positive breast cancer patients treated with trastuzumabbased therapy and identified a proportion of patients refractory to trastuzumab that harbor amplification of the cyclin E gene. Our results suggest that cyclin E amplification decreases trastuzumab sensitivity and may provide the rationale to test the efficacy of CDK2 inhibitors in breast cancer patients with cyclin E amplification that escaped trastuzumab therapy. American Association for Cancer Research 615 Chestnut St. 17th Floor Philadelphia, PA 19106
2 Cyclin E amplification, a novel mechanism of resistance to trastuzumab in HER2 amplified breast cancer Maurizio Scaltriti, PhD Experimental Therapeutics Program Vall d Hebron Institute of Oncology Barcelona, Spain
3 Disclosures: Nothing to disclose
4 Mechanisms of trastuzumab activity Other HERs Ligands HER2 Immune Response (ADCC) -Trastuzumab Proliferation RAS/RAF/MEK/ERK Cell Cycle, Survival PI3K/AKT/mTOR p27
5 Mechanisms of resistance to trastuzumab Confirmed mechanisms in the clinic Hyperactivation of the PI3K Pathway Nagata et al, 2004 Cancer Cell Berns et al, 2007 Cancer Cell Eichhorn et al, 2008 Cancer Res Presence of truncated forms of HER2 (p95her2) Scaltriti et al, 2007 JNCI Loss of HER2 expression Mittendorf et al, 2009 Clin Cancer Res
6 Selection of trastuzumab resistant (R) cells R do not respond to the antiproliferative effects of trastuzumab in vitro Relative Proliferation Trastuzumab (nm)
7 Selection of trastuzumab resistant (R) cells R do not respond to the antiproliferative effects of trastuzumab in vitro Relative Proliferation Trastuzumab 18 months Trastuzumab (nm)
8 Selection of trastuzumab resistant (R) cells R do not respond to the antiproliferative effects of trastuzumab in vitro Relative Proliferation Trastuzumab 18 months Relative Proliferation R Trastuzumab (nm) Trastuzumab (nm) (IC50>1uM)
9 Characterization of R cells R cells do not exhibit previously known mechanisms of trastuzumab resistance R R Tras (100nM) pher2 HER2 pigfr IGFR pakt Akt Percentage of cells R G1 S G2 pmapk 50 MAPK Cyclin D Tras (nm) p27 actin
10 Characterization of R cells R cells do not exhibit previously known mechanisms of trastuzumab resistance R R Tras (100nM) pher2 HER2 pigfr IGFR pakt Akt Percentage of cells R G1 S G2 pmapk 50 MAPK Cyclin D Tras (nm) p27 actin
11 Characterization of R cells R cells do not exhibit previously known mechanisms of trastuzumab resistance R R Tras (100nM) pher2 HER2 pigfr IGFR pakt Akt Percentage of cells R G1 S G2 pmapk 50 MAPK Cyclin D Tras (nm) p27 actin
12 Characterization of R cells R cells do not exhibit previously known mechanisms of trastuzumab resistance R R Tras (100nM) pher2 HER2 pigfr IGFR pakt Akt Percentage of cells R G1 S G2 pmapk 50 MAPK Cyclin D Tras (nm) p27 actin
13 Characterization of R cells R cells do not exhibit previously known mechanisms of trastuzumab resistance R R Tras (100nM) pher2 HER2 pigfr IGFR pakt Akt Percentage of cells R G1 S G2 pmapk 50 MAPK Cyclin D Tras (nm) p27 actin
14 Characterization of R cells R cells present cyclin E amplification and overexpression CNV1 CNV2 CNV1 (Chr.19) UQCRFS1 POP4 PLEKHF1 C19orf12 CCNE1 C19orf2 ZNF536 CNV2 (Chr.14) GPR65 GALC R R Tras (100nM) Cyclin E R MKN7 prb(s780) RB p27 actin IHC: Cyclin E
15 Cyclin E/CDK2 addiction of R cells Cyclin E expression modulates trastuzumab sensitivity Knockdown Relative ABS 570nm sicontrol Overexpression Relative ABS 570nm sicontrol + Tras siccne1 siccne1 + Tras control Tras 100nM R R R CE1 CE2 Cyclin E tubulin siccne1 IP:Cyclin E WB:Cyclin E 0 CE1 CE2
16 Cyclin E/CDK2 addiction of R cells CDK2 inhibition decreases proliferation of R cells CDK2 inhibitor: Cmpd 5 (Cyclacel) is trisubstituted purine derivative of seliciclib. IC50 300nM Absorbance at 570nM BT-474 BT-474R Absorbance at 570nM Cmpd5 Ratio to CDK2 CDK CDK CDK CDK LKB CDK CDK BT-474 CLK BT CE CLK CDK control Tras Cdk2i T+C control Tras Cdk2i T+C
17 Cyclin E/CDK2 addiction of R cells CDK2 inhibition leads to G1 arrest and increases cell death of R cells Percentage of cells R G1 S G2 Tras 10 nm Cdk2i 300 nm % Cells % Cells Sub G Annexin V R Tras(100nM) Cdk2i(300nM) R Tras(100nM) Cdk2i(300nM)
18 Cyclin E/CDK2 addiction of R cells CDK2 inhibition decreases prb and promotes cleavage of Parp R Tras(100nM) Cdk2i(300nM) pher2 HER2 prb(s807) prb(s780) Rb cleaved Parp p27
19 Cyclin E/CDK2 addiction of R cells CDK2 inhibition reduces tumor growth of R-derived xenografts
20 Cyclin E amplification/overexpression in HER2+ patients Cyclin E positive: FISH ratio 1.5 and IHC nuclear staining 30 H-Score Patient 1: CCNE1 WT CCNE1 probe DAPI Patient 2: CCNE1 Amp
21 Cyclin E amplification/overexpression in HER2+ patients and resistance to trastuzumab Cohort of patients with cyclin E + (n=16) Metastatic HER2 + breast cancer Cyclin E amplification/overexpression Treated with 1 st -line trastuzumab-containing therapy Compared to similar cohort of patients cyclin E (n=8) No ciclin E (n=8) Blue: no cyclin E amplif/nuclear staining Green: High cyclin ciclin E amplif/nuclear E (n=13) staining PFS probability Median PFS: 4 months vs 13 months P value.046* 4 m 13 m *Breslow test Months
22 Cyclin E amplification/overexpression in HER2+ patients and resistance to trastuzumab Clinical benefit rate Patients (%) No cyclin E High cyclin E!" * nuclear staining 30 H score. P value.030 Clinical benefit rate: CR+PR+SD>6 months.
23 Conclusions cells with acquired resistance to trastuzumab present amplification and overexpression of cyclin E Cyclin E overexpression modulates sensitivity to trastuzumab R cells are addicted to cyclin E-dependent CDK2 activity Amplification/overexpression (nuclear staining) of cyclin E correlates with lower therapeutic response to trastuzumab-based therapy CDK2 inhibition could be a valid strategy to target cyclin E amplified/overexpressing HER2 positive breast cancer
24 Acknowledgments
Resistance to anti-her2 therapies. Service d Oncologie Médicale
Resistance to anti-her2 therapies Pr David Khayat Service d Oncologie Médicale Groupe Hospitalier Pitié Salpêtrière -Paris Disclosure statment Trastuzumab in HER2+ MBC A major impact but resistance will
More informationTargeting the PI3K-Akt-mTOR pathway with GDC-0068, a novel selective ATP competitive Akt inhibitor
Targeting the PI3K-Akt-mTOR pathway with GDC-0068, a novel selective ATP competitive Akt inhibitor Josep Tabernero, Andrés Cervantes, Cristina Saura, Desamparados Roda, Yibing Yan, Kui Lin, Sumati Murli,
More informationLAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI)
LAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI) Prim Mr Sc Dr Suzana Vasović Institute for oncology and radiology of Serbia UMOS, X Conference, 16.05.2015 Belgrade How do we
More informationNovel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance
Novel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance Richard S. Finn, MD Division of Hematology/ Oncology Director, Translational Oncology Laboratory Geffen School of Medicine
More informationTranslational Platform for the Development of Targeted Therapeutics
Translational Platform for the Development of Targeted Therapeutics Ondřej Kalous, MD Associate Project Scientist UCLA Translational Oncology Research Laboratories (TORL) Jonsson Comprehensive Cancer Center
More informationLigand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Article Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Teemu T. Junttila, 1 Robert W. Akita, 1 Kathryn Parsons, 1 Carter
More informationSupplementary Information
Supplementary Information - chimeric fusion transcript in human gastric cancer promotes tumorigenesis through activation of PI3K/AKT signaling Sun Mi Yun, Kwiyeom Yoon, Sunghoon Lee, Eunjeong Kim, Seong-Ho
More informationBreast Cancer Carcinogenesis: Mechanisms and Pathways in Hormone Receptor Positive Disease
Breast Cancer Carcinogenesis: Mechanisms and Pathways in Hormone Receptor Positive Disease 1 Nearly Two-Thirds of Metastatic Breast Cancers Express Hormone Receptors Breast cancer tumors are often classified
More informationPIK3CA Mutations in HER2-Positive Breast Cancer
2016.4.29. GBCC PIK3CA Mutations in HER2-Positive Breast Cancer Seock-Ah Im, MD, PhD. Department of Internal Medicine Seoul National University Hospital Contents Introduction TCGA data HER2 signaling pathway
More informationFang et al. NMuMG. PyVmT unstained Anti-CCR2-PE MDA-MB MCF MCF10A
A NMuMG PyVmT 16.5+.5 47.+7.2 Fang et al. unstained Anti-CCR2-PE 4T1 Control 37.6+6.3 56.1+.65 MCF1A 16.1+3. MCF-7 3.1+5.4 MDA-M-231 42.1+5.5 unstained Secondary antibody only Anti-CCR2 SUPPLEMENTAL FIGURE
More informationTargeting the PI3K Pathway in the Therapy of Breast Cancer: Current Status and Future Directions. José Baselga MD, PhD Physician-in-Chief
Targeting the PI3K Pathway in the Therapy of Breast Cancer: Current Status and Future Directions José Baselga MD, PhD Physician-in-Chief PI3K and Breast Cancer Overview The Pathway PI3K drives resistance
More informationRSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
Amendment history: Corrigendum (March 2014) RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer Violeta Serra,, So Young Kim, José Baselga J Clin Invest. 2013;123(6):2551-2563. https://doi.org/10.1172/jci66343.
More informationPreexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma
The Journal of Clinical Investigation Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma Jihun Kim, 1,2,3 Cameron Fox, 1 Shouyong Peng, 1,2 Mark
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationTrastuzumab e carcinoma mammario HER2+: attività e possibili meccanismi di resistenza
Innovazioni terapeutiche in Oncologia Medica Cagliari, 23-24 24 giugno 2005 Trastuzumab e carcinoma mammario +: attività e possibili meccanismi di resistenza U.O.A.D.U. Oncologia Medica ed Ematologia I.R.C.C.
More informationTratamiento neoadyuvante: Enfermedad residual como marcador de resistencia Carlos L. Arteaga, MD Vanderbilt-Ingram Cancer Center Vanderbilt
Tratamiento neoadyuvante: Enfermedad residual como marcador de resistencia Carlos L. Arteaga, MD Vanderbilt-Ingram Cancer Center Vanderbilt University Neoadjuvant (preoperative) therapy Surgery Systemic
More informationSupplementary Materials for
www.sciencesignaling.org/cgi/content/full/7/318/ra29/dc1 Supplementary Materials for Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer
More informationAP VP DLP H&E. p-akt DLP
A B AP VP DLP H&E AP AP VP DLP p-akt wild-type prostate PTEN-null prostate Supplementary Fig. 1. Targeted deletion of PTEN in prostate epithelium resulted in HG-PIN in all three lobes. (A) The anatomy
More informationDetermination Differentiation. determinated precursor specialized cell
Biology of Cancer -Developmental Biology: Determination and Differentiation -Cell Cycle Regulation -Tumor genes: Proto-Oncogenes, Tumor supressor genes -Tumor-Progression -Example for Tumor-Progression:
More informationNeratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT basket trial
Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT basket trial Anishka D Souza 1, Lynda D. Roman 1, Cristina Saura 2, Irene Braña 2, Geoffrey I. Shapiro
More informationTranslating cancer biology into medicines BIO CEO Investor Conference NASDAQ CYCC - February 12, 2018
CYC 682 Translating cancer biology into medicines BIO CEO Investor Conference NASDAQ CYCC - February 12, 2018 Disclaimer This presentation contains forward-looking statements within the meaning of the
More informationSupplementary Online Content
Supplementary Online Content Fumagalli D, Venet D, Ignatiadis M, et al. RNA Sequencing to predict response to neoadjuvant anti-her2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial.
More informationMolecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer Rita Nahta, Emory University Journal Title: ISRN Oncology Volume: Volume 2012, Number 2012 Publisher: Hindawi Publishing
More informationSupplementary Figure 1
Combination index (CI) Supplementary Figure 1 2. 1.5 1. Ishikawa AN3CA Nou-1 Hec-18.5...2.4.6.8 1. Fraction affected (Fa) Supplementary Figure 1. The synergistic effect of PARP inhibitor and PI3K inhibitor
More informationA View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.
A View to the Future: Science to Survivorship Symposium September 26, 2009 The Development of Targeted Therapy for Melanoma Michael Davies, M.D., Ph.D. Assistant Professor, Melanoma Medical Oncology How
More informationEmerging Advances in Metastatic Breast Cancer
Emerging Advances in Metastatic Breast Cancer Bryan P. Schneider, MD Assistant Professor of Medicine & Medical Molecular Genetics IU Simon Cancer Center AT LEAST THREE types of breast cancer TNBC HER2+
More informationSupplementary Methods: IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer
S1 of S6 Supplementary Methods: IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer Shang-Gin Wu, Tzu-Hua Chang, Meng-Feng Tsai, Yi-Nan Liu, Chia-Lang
More informationEPIGENETIC RE-EXPRESSION OF HIF-2α SUPPRESSES SOFT TISSUE SARCOMA GROWTH
EPIGENETIC RE-EXPRESSION OF HIF-2α SUPPRESSES SOFT TISSUE SARCOMA GROWTH Supplementary Figure 1. Supplementary Figure 1. Characterization of KP and KPH2 autochthonous UPS tumors. a) Genotyping of KPH2
More informationMechanisms of hormone drug resistance
Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, 16-17 th May 2015. Hormone receptor-positive breast cancer (HR+
More informationRSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
Research article RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer Violeta Serra, 1 Pieter J.A. Eichhorn, 2 Celina García-García, 1 Yasir H. Ibrahim, 1 Ludmila Prudkin, 3 Gertrudis
More informationTITLE: Investigation of the Akt/Pkb Kinase in the Development of Hormone- Independent Prostate Cancer
AD Award Number: TITLE: Investigation of the Akt/Pkb Kinase in the Development of Hormone- Independent Prostate Cancer PRINCIPAL INVESTIGATOR: Linda A. degraffenried, PhD CONTRACTING ORGANIZATION: University
More informationBreast cancer update. Iryna Kuchuk, MD Oncology department Meir Medical Center
Breast cancer update Iryna Kuchuk, MD Oncology department Meir Medical Center Overview Cancer Death Rates* Among Women, US,1930-2009 Factors Associated with Reduction In Breast Cancer Mortality Early
More informationAntitumor Activity of CUDC-305, a Novel Oral HSP90 Inhibitor, in Solid and Hematological Tumor Xenograft Models
Antitumor Activity of CUDC-5, a Novel Oral HSP Inhibitor, in Solid and Hematological Tumor Xenograft Models Rudi Bao, MD/PhD April 1, 2 AACR 1th Annual Meeting 2 Experimental and Molecular Therapeutics
More informationSupplementary Figure 1: Tissue of Origin analysis on 152 cell lines. (a) Heatmap representation of the 30 Tissue scores for the 152 cell lines.
Supplementary Figure 1: Tissue of Origin analysis on 152 cell lines. (a) Heatmap representation of the 30 Tissue scores for the 152 cell lines. The scores summarize the global expression of the tissue
More informationTITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer
AD Award Number: TITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer PRINCIPAL INVESTIGATOR: Linda A. degraffenried, Ph.D. CONTRACTING ORGANIZATION: The
More informationMechanism for targeting CDK4, BTK and PI3K in Mantle Cell Lymphoma. Selina Chen-Kiang, Ph.D. Weill Cornell Medicine
Mechanism for targeting CDK4, BTK and PI3K in Mantle Cell Lymphoma Selina Chen-Kiang, Ph.D. Weill Cornell Medicine Goal To develop mechanism-based therapy in mantle cell lymphoma Effective, tolerable,
More informationSupplementary Table 1. Characterization of HNSCC PDX models established at MSKCC
Supplementary Table 1. Characterization of HNSCC PDX models established at MSKCC Supplementary Table 2. Drug content and loading efficiency estimated with F-NMR and UV- Vis Supplementary Table 3. Complete
More informationSupplemental Figure S1A Notch1
Supplemental Figure S1A Notch1 erage) epth of Cove ormalized De Log1(No Notch exons Figure S1: A) Relative coverage of Notch1 and Notch 2 exons in HCC2218, HCC1187, MB157, MDA-MB157 cell lines. Blue color
More informationCyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
/, Vol. 6, No.2 Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS Barbie Taylor-Harding 1, Paul-Joseph Aspuria 1, Hasmik Agadjanian 1, Dong-Joo Cheon 1, Takako
More informationPhospho-PRAS40 Thr246 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer
ONCOLOGY LETTERS 9: 785-789, 2015 Phospho-PRAS40 Thr246 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer KAI YUAN, HONGYAN WU, YULONG WANG, HONGQIANG CHEN, MINGWEN
More informationHER2 FISH pharmdx TM Interpretation Guide - Breast Cancer
P A T H O L O G Y HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer For In Vitro Diagnostic Use FDA approved as an aid in the assessment of patients for whom Herceptin TM (trastuzumab) treatment
More informationJOSÉ BASELGA. Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
The Oncologist Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer JOSÉ BASELGA Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA Disclosures: José Baselga: Consultant/advisory
More informationPriti Lal, MD, 1 Paulo A. Salazar, 1 Clifford A. Hudis, MD, 2 Marc Ladanyi, MD, 1 and Beiyun Chen, MD, PhD 1. Abstract
Anatomic Pathology / DUAL- VS SINGLE-COLOR SCORING IN IMMUNOHISTOCHEMICAL AND FISH HER-2 TESTING HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ Hybridization
More informationDiscovery Dataset. PD Liver Luminal B/ Her-2+ Letrozole. PD Supraclavicular Lymph node. PD Supraclavicular Lymph node Luminal B.
Discovery Dataset 11T pt1cpn2am1(liver) 2009 2010 Liver / Her-2+ 2011 Death Letrozole CHT pt1cpn0(sn)m0 Supraclavicular Lymph node Death 12T 2003 2006 2006 2008 Anastrozole Local RT+Examestane Fulvestrant
More informationNature Medicine: doi: /nm.3559
Supplementary Note 1. A sample alteration report. Each alteration nominated by PHIAL is curated to answer specific fields that are intended to guide physician interpretation. Gene Alteration Patient ID
More informationURI Is an Oncogene Amplified in Ovarian Cancer Cells and Is Required for Their Survival
Article Is an Oncogene Amplified in Ovarian Cancer Cells and Is Required for Their Survival Jean-Philippe Theurillat,,, Stefan Christian Metzler,, Nico Henzi, Nabil Djouder, Marianne Helbling, Anna-Kathrin
More informationTechnology Hurdles: Drug Developer Perspective
Technology Hurdles: Drug Developer Perspective Robert Mass, MD Senior Director Genentech, Inc. June 8, 2009 Diagnostic challenges Genentech has been committed to personalized drug development in oncology
More informationBCHM3972 Human Molecular Cell Biology (Advanced) 2013 Course University of Sydney
BCHM3972 Human Molecular Cell Biology (Advanced) 2013 Course University of Sydney Page 2: Immune Mechanisms & Molecular Biology of Host Defence (Prof Campbell) Page 45: Infection and Implications for Cell
More informationApplication of Whole Genome Microarrays in Cancer: You should be doing this test!!
Application of Whole Genome Microarrays in Cancer: You should be doing this test!! Daynna Wolff, Ph.D. Director, Cytogenetics and Genomics Disclosures Clinical Laboratory Director and Employee, Medical
More informationSupplementary Figure 1. Basal level EGFR across a panel of ESCC lines. Immunoblots demonstrate the expression of phosphorylated and total EGFR as
Supplementary Figure 1. Basal level EGFR across a panel of ESCC lines. Immunoblots demonstrate the expression of phosphorylated and total EGFR as well as their downstream effectors across a panel of ESCC
More informationAACR 101st Annual Meeting 2010, Washington D.C. Experimental and Molecular Therapeutics Section 29; Abstract #3855
Investigation of the Growth Inhibitory Activity of the MEK Inhibitor ARRY-162 in Combination with Everolimus in a Variety of KRas and PI3K Pathway Mutant Cancers Brian Tunquist, Tyler Risom, Debbie Anderson,
More informationSupplementary Information
Supplementary Information Figure S1. Int6 gene silencing efficiency. (A) Western Blot analysis of Int6 expression at different times after sirna transfection. Int6 expression is strongly silenced in Int6
More informationApoptosis Oncogenes. Srbová Martina
Apoptosis Oncogenes Srbová Martina Cell Cycle Control point Cyclin B Cdk1 Cyclin D Cdk4 Cdk6 Cyclin A Cdk2 Cyclin E Cdk2 Cyclin-dependent kinase (Cdk) have to bind a cyclin to become active Regulation
More informationTITLE: Cyclin E, A Powerful Predictor of Survival in Breast Cancer-A Prospective Study
AD Award Number: DAMD17-02-1-0452 TITLE: Cyclin E, A Powerful Predictor of Survival in Breast Cancer-A Prospective Study PRINCIPAL INVESTIGATOR: Khandan Keyomarsi, Ph.D. CONTRACTING ORGANIZATION: MD Anderson
More informationSupplemental Materials. STK16 regulates actin dynamics to control Golgi organization and cell cycle
Supplemental Materials STK16 regulates actin dynamics to control Golgi organization and cell cycle Juanjuan Liu 1,2,3, Xingxing Yang 1,3, Binhua Li 1, Junjun Wang 1,2, Wenchao Wang 1, Jing Liu 1, Qingsong
More informationSupplementary Information. Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent
Supplementary Information Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent Authors: Susanne Kossatz a, Christian Brand a, Stanley Gutiontov b, Jonathan T.C. Liu c, Nancy
More informationAward Number: W81XWH TITLE: Characterizing an EMT Signature in Breast Cancer. PRINCIPAL INVESTIGATOR: Melanie C.
AD Award Number: W81XWH-08-1-0306 TITLE: Characterizing an EMT Signature in Breast Cancer PRINCIPAL INVESTIGATOR: Melanie C. Bocanegra CONTRACTING ORGANIZATION: Leland Stanford Junior University Stanford,
More informationAssessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray
Assessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray Hui Chen, Aysegul A Sahin, Xinyan Lu, Lei Huo, Rajesh R Singh, Ronald Abraham, Shumaila Virani, Bal Mukund Mishra, Russell Broaddus,
More informationDisrupting the Cell Cycle to Treat AML, MDS and other Cancers
CYC 682 Disrupting the Cell Cycle to Treat AML, MDS and other Cancers February 2015 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor provisions of
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationUpdate mbc. endokrine Therapie
Update mbc endokrine Therapie HR neg ER pos Endokrine Resistenz Endokrine Therapie 1 st line Postmenopause AI/Tam/Fulvestrant 84% AI+ Fulvestrant 33% AI (Tam) + Everolimus 84% AI + CDK4/6 92% Prämenopause
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationSupplementary Figure 1
Supplementary Figure 1 Supplementary Fig. 1: Quality assessment of formalin-fixed paraffin-embedded (FFPE)-derived DNA and nuclei. (a) Multiplex PCR analysis of unrepaired and repaired bulk FFPE gdna from
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More information1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli
Dott.ssa Sara Redaelli 13/10/2017 1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance Tumor Heterogeneity: Oncogenic Drivers in NSCLC The Promise of Genotype-Directed Therapy
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationTEB. Id4 p63 DAPI Merge. Id4 CK8 DAPI Merge
a Duct TEB b Id4 p63 DAPI Merge Id4 CK8 DAPI Merge c d e Supplementary Figure 1. Identification of Id4-positive MECs and characterization of the Comma-D model. (a) IHC analysis of ID4 expression in the
More informationTargeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer
Oncogene (2018) 37:2251 2269 https://doi.org/10.1038/s41388-017-0108-9 ARTICLE Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive
More informationSupplementary Information Titles Journal: Nature Medicine
Supplementary Information Titles Journal: Nature Medicine Article Title: Corresponding Author: Supplementary Item & Number Supplementary Fig.1 Fig.2 Fig.3 Fig.4 Fig.5 Fig.6 Fig.7 Fig.8 Fig.9 Fig. Fig.11
More informationHunk is required for HER2/neu-induced mammary tumorigenesis
Research article Hunk is required for HER2/neu-induced mammary tumorigenesis Elizabeth S. Yeh, 1 Thomas W. Yang, 1 Jason J. Jung, 1 Heather P. Gardner, 1 Robert D. Cardiff, 2 and Lewis A. Chodosh 1 1 Department
More informationSupplementary Figure 1. Characterization of NMuMG-ErbB2 and NIC breast cancer cells expressing shrnas targeting LPP. NMuMG-ErbB2 cells (a) and NIC
Supplementary Figure 1. Characterization of NMuMG-ErbB2 and NIC breast cancer cells expressing shrnas targeting LPP. NMuMG-ErbB2 cells (a) and NIC cells (b) were engineered to stably express either a LucA-shRNA
More informationTumor Biology and Experimental Therapeutics Program
Tumor Biology and Experimental Therapeutics Program Translational Genomic Unit Main research projects: - Characterization of the mechanism of platinum resistance in Epithelial ovarian cancer. - Analysis
More informationLayered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue
Page 1 The need for multiplex detection of tissue biomarkers. There is a constant and growing demand for increased biomarker analysis in human tissue specimens. Analysis of tissue biomarkers is key to
More informationSD-1 SD-1: Cathepsin B levels in TNF treated hch
SD-1 SD-1: Cathepsin B levels in TNF treated hch. A. RNA and B. protein extracts from TNF treated and untreated human chondrocytes (hch) were analyzed via qpcr (left) and immunoblot analyses (right) for
More informationMET skipping mutation, EGFR
New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM
More informationTranslating cancer biology into medicines NASDAQ CYCC January 2018
CYC 682 Translating cancer biology into medicines NASDAQ CYCC January 2018 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private
More informationOncogenes and Tumor. supressors
Oncogenes and Tumor supressors From history to therapeutics Serge ROCHE Neoplastic transformation TUMOR SURESSOR ONCOGENE ONCOGENES History 1911 1960 1980 2001 Transforming retrovirus RSV v-src is an oncogene
More informationGenome of Hepatitis B Virus. VIRAL ONCOGENE Dr. Yahwardiah Siregar, PhD Dr. Sry Suryani Widjaja, Mkes Biochemistry Department
Genome of Hepatitis B Virus VIRAL ONCOGENE Dr. Yahwardiah Siregar, PhD Dr. Sry Suryani Widjaja, Mkes Biochemistry Department Proto Oncogen and Oncogen Oncogen Proteins that possess the ability to cause
More informationMolecular Probes Introducing 14 new probes
Molecular Probes Introducing 14 new probes Gene and Chromosome Probes Dual Colour ISH INFORM HER2 Dual ISH DNA Probe Cocktail Assay Product Part Number INFORM HER2 Dual ISH DNA Probe Cocktail 800-4422
More informationOptimizing anti-her-2 therapies for ABC Potential role of immunotherapy. Javier Cortes, Ramon y
Optimizing anti-her-2 therapies for ABC Potential role of immunotherapy Javier Cortes, Ramon y Cajal University Hospital, Madrid, Spain Vall d Hebron Institute of Oncology (VHIO), Medica Scientia Innovation
More informationLOTUS (NCT ) randomized phase II trial
Overall survival update of the double-blind placebocontrolled randomized phase 2 LOTUS trial of firstline ipatasertib + paclitaxel for locally advanced/metastatic triple-negative breast cancer Rebecca
More informationSummary... 2 TRANSLATIONAL RESEARCH Tumour gene expression used to direct clinical decision-making for patients with advanced cancers...
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 TRANSLATIONAL RESEARCH... 3 Tumour gene expression used to direct clinical decision-making for patients with advanced
More informationHER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam
HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular
More informationSALSA MLPA probemix P315-B1 EGFR
SALSA MLPA probemix P315-B1 EGFR Lot B1-0215 and B1-0112. As compared to the previous A1 version (lot 0208), two mutation-specific probes for the EGFR mutations L858R and T709M as well as one additional
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationIntergenic Fusions in Advanced HR+ Breast Cancer
Intergenic Fusions in Advanced HR+ Breast Cancer Leif W. Ellisen, MD, PhD Program Director, Breast Medical Oncology Disclosures: Lief W. Ellisen, MD, PhD, has disclosed no relevant financial relationships.
More informationNeoplasia 2018 lecture 4. Dr Heyam Awad MD, FRCPath
Neoplasia 2018 lecture 4 Dr Heyam Awad MD, FRCPath ILOS To understand the concept of the hallmarks of cancer and that they are phenotypic changes needed in all cancer cells. To list the tumor enablers
More informationCohort D Xentuzumab + abemaciclib + fulvestrant (500 mg/month) Key exclusion criteria RP2D-4 NSCLC. Cohort F Xentuzumab + abemaciclib + fulvestrant
A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, including hormone receptor-positive, HER2-negative breast cancer (plus endocrine therapy) Douglas
More informationC-Phycocyanin (C-PC) is a n«sjfc&c- waefc-jduble phycobiliprotein. pigment isolated from Spirulina platensis. This water- soluble protein pigment is
' ^Summary C-Phycocyanin (C-PC) is a n«sjfc&c- waefc-jduble phycobiliprotein pigment isolated from Spirulina platensis. This water- soluble protein pigment is of greater importance because of its various
More informationKDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling
Research article KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling Klaus W. Wagner, 1,2 Hunain Alam, 1 Shilpa S. Dhar, 1 Uma Giri, 3 Na Li, 1 Yongkun Wei, 1 Dipak Giri, 4 Tina
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationCANCER. Clinical Validation of Breast Cancer Predictive Markers
Clinical Validation of Breast Cancer Predictive Markers David Hicks, MD Loralee McMahon, MS, HTL(ASCP) CANCER The human body is composed of billions of highly regulated cells Cancer cells no longer respond
More information(A) RT-PCR for components of the Shh/Gli pathway in normal fetus cell (MRC-5) and a
Supplementary figure legends Supplementary Figure 1. Expression of Shh signaling components in a panel of gastric cancer. (A) RT-PCR for components of the Shh/Gli pathway in normal fetus cell (MRC-5) and
More informationTherapeutic Resistance to HER2 Targeted Therapies. Neil Spector, M.D Duke Cancer Institute Duke University Medical Center
Therapeutic Resistance to HER2 Targeted Therapies Neil Spector, M.D Duke Cancer Institute Duke University Medical Center Relevant Financial Disclosures Millennium/Takeda Pharmaceuticals (consultant, sponsored
More informationOne-two Punch to Deadly Pancreatic Cancer: Targeted Therapy with Mab AR9.6 and Rapamycin Analogue ACP Jan 2016
One-two Punch to Deadly Pancreatic Cancer: Targeted Therapy with Mab AR9.6 and Rapamycin Analogue ACP 2127 Jan 2016 AmrutBio Overview A subsidiary of Quest PharmaTech, a publicly traded (QPT-TSXV), Canadian
More informationDox. R26-rtTA Tyr-CreERT2. any ink/arf, no rtta (n=8) ink/arf +/+ (n=5) Day 0 Day 11 Day 18 Day 28
A 4OHT Dox hraf iip tumors inras ddh 2 O -RT Ink/Arf / Pten l/ l R26-lsl-rtTA Tyr-reERT2 TetO-hRAF V6E Ink/Arf / Pten / R26-rtTA Tyr-reERT2 TetO-hRAF V6E Ink/Arf / Pten / R26-rtTA Tyr-reERT2 TetO-hRAF
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #450 (NQF 1858): Trastuzumab Received By Patients With AJCC Stage I (T1c) III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy National Quality Strategy Domain: Effective Clinical
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationBIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2018
THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2018 Anisley Valenciaga PhD Candidate Cell cycle regulators and transcriptional targeting in Medullary Thyroid Cancer 04/06/18 BRT
More informationLa farmacologia dei CDK4/6 inibitori
La farmacologia dei CDK4/6 inibitori Romano Danesi UO Farmacologia clinica e Farmacogenetica Università di Pisa The role of cyclin D CDK4/6 p16 Rb pathway in the cell cycle Debu Tripathy et al. Clin Cancer
More information